In today’s recent session, 2.32 million shares of the Pacific Biosciences of California Inc (NASDAQ:PACB) have been traded, and its beta is 2.20. Most recently the company’s share price was $1.10, and it changed around -$0.01 or -0.89% from the last close, which brings the market valuation of the company to $330.08M. PACB at last check was trading at a discount to its 52-week high of $2.72, offering almost -147.27% off that amount. The share price’s 52-week low was $1.06, which indicates that the recent value has risen by an impressive 3.64% since then.
Pacific Biosciences of California Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.27. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 8 recommended PACB as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Instantly PACB has been showing red trend so far today with a performance of -0.89% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.1600 on recent trading dayincreased the stock’s daily price by 5.17%. The company’s shares are currently down -39.89% year-to-date, but still down -0.89% over the last five days. On the other hand, Pacific Biosciences of California Inc (NASDAQ:PACB) is -10.56% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 63.33% from its current value. Analyst projections state that PACB is forecast to be at a low of $2 and a high of $4.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.55%. Pacific Biosciences of California Inc earnings are expected to increase by 35.84% in 2025, but the outlook is positive 24.80% per year for the next five years.
PACB Dividends
Pacific Biosciences of California Inc’s next quarterly earnings report is expected to be released in June.
VANGUARD GROUP INC, with 9.5449% or 26.0 million shares worth $35.62 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF were the top two Mutual Funds as of Mar 31, 2025 . The former held 21.75 shares worth $24.03 million, making up 7.25% of all outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held roughly 11.63 shares worth around $12.85 million, which represents about 3.88% of the total shares outstanding.
